GE HealthCare Expands Cardiovascular Ultrasound Portfolio
Three new Vivid systems target different cardiovascular imaging settings and have received CE Mark, with US FDA clearance pending.
Three new Vivid systems target different cardiovascular imaging settings and have received CE Mark, with US FDA clearance pending.
The $35 million expansion will advance artificial intelligence-powered ultrasound solutions for trauma assessment and mass casualty incident preparedness.
The updated systems include a new tool for guiding peripheral nerve blocks and features to simplify bladder and cardiac assessments.
Three new Vivid systems target different cardiovascular imaging settings and have received CE Mark, with US FDA clearance pending.
The NeedleVue LC1 Ultrasound System is designed to provide sub-millimeter level guidance during interventional procedures.
Read MoreThe device combines ultrasound elastography with AI features to help clinicians assess liver fat and stiffness at the point of care for patients with chronic liver disease.
Read MoreExclusive to the Sonosite LX system, the new transducer aims to improve diagnostic confidence and procedural precision in superficial imaging.
Read MoreThe ultrasound system with integrated AI software is designed to provide anatomical guidance during needle or catheter placement.
Read MoreDesigned to assist with needle-based interventions, the system aims to reduce user variability and enhance procedural efficiency.
Read MoreThe system allows US healthcare providers to transform traditional 2D ultrasound into AI-supported 3D tomographic imaging.
Read MoreThe partnership adds Vivid, LOGIQ, Versana, Venue, and Vscan Air ultrasound lines to Probo’s offerings.